Latest asthma Stories

MADISON, Wis., March 5, 2013 /PRNewswire/ -- Asthmapolis today announced an investigation featuring the system in the remote monitoring of inhaled bronchodilator use and weekly feedback about asthma management has been published in the latest issue of the scientific journal PLOS ONE (http://dx.plos.org/10.1371/journal.pone.0055335). The study found improved asthma control and a decline in day-to-day asthma symptoms for participants receiving Asthmapolis' weekly email reports and...

redOrbit Staff & Wire Reports - Your Universe Online Researchers at the Brigham and Women’s Hospital (BWH) in Boston have discovered a molecule that controls cells responsible for decreasing airway inflammation in asthma patients, and their discovery could lead to new treatments for the millions of Americans that suffer from the disease. The molecule is known as lipoxin A4, and according to the researchers, it is responsible for resolving inflammation. It accomplishes this in two...

People with COPD, asthma, emphysema, bronchitis, CF, and lung transplants are using the Spiro PD Personal Spirometer to monitor their lung health and to get “baseline” readings to compare with peak allergy season. For more information, visit http://www.SpiroPD.com. Allentown, Pennsylvania (PRWEB) February 26, 2013 The recent blizzard in the Northeast notwithstanding, many areas of the U.S. have experienced a mild winter, with unseasonably warm weather. A mild winter can signify an...

Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting SOUTH SAN FRANCISCO, Calif., Feb. 26, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) presented data from its Phase 1/2 study in persistent asthma for KB002 (precursor chimeric anti-GM-CSF monoclonal antibody to KB003) at the American Academy of Allergy, Asthma & Immunology (AAAI) Annual Meeting in Austin, Texas. The findings demonstrated preliminary...

Study identifies possible therapeutic target to treat asthma and COPD New research examines the role of PKC in airway smooth muscle contraction and raises the possibility that this enzyme could be a therapeutic target for treating asthma, COPD, and other lung diseases. In the lungs, pathological increases in the contraction of the smooth muscle cells (SMCs) lining airway walls—a process that decreases airflow—contribute to the chain of events leading to asthma and COPD, two common...

MADISON, Wis., Feb. 26, 2013 /PRNewswire/ -- Asthmapolis today announced the company won the inaugural Bluetooth® Breakthrough Award in the Product Category from the Bluetooth Special Interest Group (SIG). The SIG received over 300 submissions from around the world, and presented the awards during a special ceremony yesterday at Mobile World Congress in Barcelona, Spain. (Photo: http://photos.prnewswire.com/prnh/20130226/CG66068) "The Asthmapolis inhaler sensor and mobile...

Company works with leading pharmaceutical organizations to advance asthma research PHILADELPHIA, Feb. 26, 2013 /PRNewswire/ -- The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced the launch of MetaMiner(TM) Asthma, the latest industry-academic-government, disease-focused collaboration dedicated to advancing the understanding of pathological pathways that cause...

For expectant moms who may contemplate the pros and cons of natural child birth or Caesarian section, a Henry Ford Hospital study suggests that C-section babies are susceptible to developing allergies by age two. Researchers found that babies born by C-section are five times more likely to develop allergies than babies born naturally when exposed to high levels of common allergens in the home such as those from dogs, cats and dust mites. The study is being presented Sunday at the...

OXFORD, England and SAN ANTONIO, February 25, 2013 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical study showing that a short course of just four doses of its ToleroMune(R) cat allergy therapy maintained improvements in patients' symptoms two years after the start of treatment. The results were presented at the 2013 Annual Meeting of the American Academy of Allergy, Asthma and...

- Phase III study published in NEJM today and to be presented tomorrow met primary endpoint in moderate-to-severe chronic idiopathic urticaria (CIU) EAST HANOVER, N.J., Feb. 24, 2013 /PRNewswire/ -- Late-breaking results from ASTERIA II, a Phase III placebo-controlled study, showed positive results in patients with moderate to severe chronic idiopathic urticaria (CIU), referred to as chronic spontaneous urticaria (CSU) outside the United States, who remained symptomatic despite...